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ABSTRACT
TREX2 is an autonomous nonprocessive 30 !50
exonuclease, suggesting that it maintains genome
integrity. To investigate TREX2’s biochemical and
cellular properties, we show that endogenous
TREX2 is expressed widely in mouse tissues and
human cell lines. Unexpectedly, endogenous human
TREX2 is predominantly expressed as a 30-kDa
protein (not 26kDa, as previously believed), which is
likely encoded by longer isoforms (TREX2
L1 and/or
TREX2
L2) that possess similar capacity for self-
association, DNA binding and catalytic activity.
Site-directed mutagenesis analysis shows that
the three functional activities of TREX2 are distinct,
yet integrated. Mutation of amino acids putatively
important for homodimerization significantly
impairs both DNA binding and exonuclease activity,
while mutation of amino acids (except R163) in the
DNA binding and exonuclease domains affects their
corresponding activities. Interestingly, however,
DNA-binding domain mutations do not impact
catalytic activity, while exonuclease domain muta-
tions diminish DNA binding. To understand TREX2
cellular properties, we find endogenous TREX2 is
down regulated during G2/M and nuclear TREX2
displays a punctate staining pattern. Furthermore,
TREX2 knockdown reduces cell proliferation. Taken
together, our results suggest that TREX2 plays an
important function during DNA metabolism and
cellular proliferation.
INTRODUCTION
To a cell, faithful replication and accurate repair of
genomic DNA are daunting tasks necessary for maintain-
ing genomic integrity. Problems with replication ﬁdelity or
DNA repair may cause genomic mutations that could
result in hereditary and sporadic human diseases such as
cancer and accelerating aging (1–4). To maintain genome
integrity, cells have evolved a built-in DNA quality
control network that consists of three highly coordinated
components: DNA damage checkpoints, DNA repair and
DNA replication. During the last decade, 30 !50 exonu-
clease activity has been identiﬁed in DNA damage
checkpoint proteins (hRad1 and hRad9) (5,6), DNA
repair proteins (MRE11, WRN, APE1, APE2,
XPF/ERCC1 and Dna2) (7–12), DNA replication poly-
merases (pold, polg and pole) (13–15) and the well-known
tumor suppressor p53 (16). In yeast, homologs corre-
sponding to these human genes (except p53) have also
been identiﬁed, illustrating that this 30 !50 exonuclease
activity is evolutionarily conserved (17). Functional
studies by gene inactivation in yeast and mouse models
have demonstrated that mutation in any one of these
genes directly leads to genomic instability (17). In fact,
mutations in some of these genes such as MRE11, WRN,
XPF, polg and p53 cause a variety of pathologies
including cancer and/or age-related diseases (18–23).
In 1999, two distinct mammalian nucleases, TREX1
(Three prime repair exonuclease, also called DNase III)
and TREX2, were found to account for the majority of
exonuclease activity in mammalian cell extracts (24,25).
Highly puriﬁed endogenous and/or recombinant TREX1
and TREX2 showed a robust 30 !50 exonuclease activity
that favors DNA substrates with 30 mismatches (25–27).
In addition, TREX1 enhances ligation eﬃciency in a polb-
mediated base excision repair assay (24) and TREX2 may
interact with pold to increase replication accuracy (28).
Protein sequence analysis shows that TREX1 and TREX2
share homology to the bacterial DNA polymerase III
holoenzyme e subunit, which exhibits 30 !50 exonuclease
(proofreading) activity. In addition, X-ray structure of the
TREX2 homodimer shows strong structural similarity to
this subunit, providing direct evidence for the structural
relationship between TREX2 functional domains and
its biochemical activities (29). Thus, both TREX1
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integrity. However, Trex1-mutant mice do not exhibit a
phenotype predicted for impaired editing of 30 termini,
since spontaneous mutations and cancer incidence
remained unchanged as compared to controls (30).
Unexpectedly, Trex1-mutant mice succumb to inﬂamma-
tory myocarditis. This phenotype could be explained by
the recent observation that TREX1 processes anomalous
DNA structures to prevent an abnormal innate immune
response that causes Aicardi-Goutieres syndrome (31).
Additionally, TREX1 exonuclease activity induces
Granzyme A-mediated cell death in concert with the
endonuclease NM23-H1 (32). At this time, the prediction
about TREX2 function is based mainly on in vitro studies;
therefore, the cellular and biological signiﬁcance of
TREX2 remains unclear.
For this study, we investigate the biochemical and
cellular properties of TREX2. We ﬁnd that TREX2 is
widely expressed in a variety of tissues and cell lines,
suggesting it has an important cellular function. In
addition to the previously reported 26-kDa TREX2, we
unexpectedly found that endogenous human TREX2 is
predominantly expressed as a 30-kDa protein, thus
leading to the isolation of two longer alternatively spliced
isoforms that maintain the same basic biochemical
function as the 26-kDa isoform. One of these isoforms,
TREX2
L1, is the predominant transcript for all samples
tested (ﬁve cancer-derived human cell lines and kidney).
Observation of a series of multiple and single amino acid
mutations in the 26-kDa isoform shows that domains
predicted to be important for homodimerization, DNA
binding and exonuclease activity by X-ray structure have
separate, yet integrated functions. We ﬁnd that single
amino acids predicted to be important for homodimeriza-
tion do not measurably alter self-association, but greatly
impair both DNA binding and catalytic activity. In
contrast, single amino acid mutations predicted to be
important for either DNA-binding or exonuclease activity
abolish their corresponding activities. In addition, exonu-
clease domain mutations reduce DNA-binding activity
while DNA-binding mutations do not aﬀect catalytic
activity. Our cellular studies show that endogenous
TREX2 is distributed in both the nucleus and the
cytoplasm, and that the nuclear fraction exhibits a
punctate staining pattern. TREX2 is regulated during
cell cycle, with lowest expression at the G2/M phase.
Functional studies illustrate that depletion of endogenous
TREX2 reduces cell proliferation. Taken together, our
results suggest that TREX2 plays a key role in DNA
metabolism.
MATERIALS AND METHODS
Plasmid construction, site-directed mutagenesis and
cloning ofTREX2 alternative splicing forms
GST-TREX2 fusion expression vectors were generated
using the human TREX2 26-kDa isoform. We generated
DNA binding defective (TREX2
BD, with triple mutations
of R163A/R165A/R167A), and exonuclease catalytic
defective (TREX2
CD, with double mutations of
H188A/D193A) open-reading frames were ampliﬁed
from the E. coli-based expression plasmids (generous
gifts from Dr Fred W. Perrino, Wake Forest University)
(29) by hTX25 forward primer and hTX23 reverse primer
(Table 1). PCR products were digested by EcoRI and
XhoI, and ligated with pGEX-6P-1 or pCMV-Tag2B to
create in-frame GST- and Flag-tagged recombinant
expression vectors. pGEX-TREX2 was used for site-
directed mutagenesis to generate dimerization defective
TREX2 (TREX2
DD, E29A/K59A/D94A/R107A/E191A)
and to generate single amino acid mutants to alanine with
primers listed in Table 1 using the QuickChange Multi
Site-Directed Mutagenesis Kit according to the manufac-
turer’s instructions (Stratagene). TREX2 alternative spli-
cing forms were customarily ampliﬁed and cloned into
pCVM6-XL based on an RNA pool of 33 human tissues
(OriGene Technologies, Inc.) by RT-PCR using primers
(Table 1) corresponding to exons 15 and 16 of TREX2
(26). Four resultant clones were sequenced; two clones
encode DNA sequence for DQ650792 (called TREX2
L2);
one clone is identical to NP_542431 (called TREX2
L1); the
last one contains partial TREX2.
Expression and purification of GST-fusion proteinfrom
Escherichia coli
BL21 cells were transformed with one of the pGEX-
TREX2 expression vectors. GST-fusion proteins were
produced and puriﬁed according to the manufacturer’s
instructions (Amersham Bioscience). To cleave TREX2
protein from GST-TREX2 fusion protein, beads-bound
GST-TREX2 was digested by PreScission protease
according to the manufacturer’s instructions (Amersham
Pharmacia). The purity and quantity of the eluted protein
were determined by SDS-PAGE/Coomassie staining and
Bradford assay.
Development of anti-TREX2 and anti-TREX1 antibodies
Beads-bound GST-fusion human 26-kDa TREX2 or
TREX1 was prepared as described previously, and was
used for immunization. Brieﬂy, before immunization, a
small amount of pre-immune serum was collected by
retro-orbital bleeding. For the primary immunization,
100mg (per mouse) of Sepharose 4B beads-bound GST-
TREX2 or GST-TREX1 was injected into three 8-week-
old C57BL/6 mice subcutaneously according to the
standard procedure (33). After 2 weeks, the continued
boosting of beads-bound GST-TREX2 or GST-TREX1
was performed weekly. Upon the third boost, the anti-
TREX2 or anti-TREX1 serum was collected every 2
weeks. The titer and speciﬁcity of the anti-TREX2 or anti-
TREX1 polyclonal antibodies were evaluated by direct-
and immunoprecipitation -western blot. Anti-b-actin
antibody (clone AC-15) and anti-Flag antibody (M2
monoclonal) were purchased from Sigma. Anti-Myc
antibody was purchased from BD Bioscience Clontech.
Celltransfection, immunoblotting and immunoprecipitation
Transfection was performed using FuGENE6
Transfection Reagent (Roche Applied Science) according
to the manufacturer’s instructions. After 48h, cells were
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HCl, pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.5% Nonidet
P-40) supplemented with appropriate amount of protease
inhibitor cocktails (Sigma). Cell lysates containing 20–
50mg of protein were subjected to 10 or 12% SDS-
polyacrylamide gel electrophoresis (PAGE) followed by
electro-transfer of resolved proteins to nylon membrane.
After blocking with non-fat milk (5%) in TBST buﬀer
(Tris-HCl, pH 7.5, 100mM NaCl and 0.1% Tween 20),
the membrane was incubated with the corresponding
primary and secondary antibodies. The immune complex
on the membrane was detected using an enhanced
chemiluminescence kit (Amersham Pharmacia Biotech).
For immunoprecipitation, 500–1000mg of total protein
(mg/ml) was incubated with 2ml of mouse polyclonal
antibodies at 48C for 2hours, followed by 1-hour
incubation with protein G-Sepharose. After ﬁve washes
with ice-cold lysis buﬀer containing protease inhibitors,
the immunoprecipitation complexes were subjected to
western blot analysis as described above.
TREX2 small interference RNA (siRNA) assay
Prior to transfection ( 24h), HeLa cells were seeded at
3 10
5/well (6-well plate) to obtain  60% conﬂuence the
following day. Three diﬀerent TREX2–siRNA duplexes
(Table 1, from DHARMACON) corresponding to human
TREX2 open-reading frames or control siRNA (Cat #:
D-001210-01, DHARMACON, CO) was transfected into
cells by TransIT-TKO transfection reagent (Cat No:
MIR 2154, Mirus, Inc.) according to the manufacturer’s
instructions. Brieﬂy, 6ml of transfection reagent was added
to 250ml of serum-free media. After 5–20min incubation,
6.25nM of each pair of siRNA was added and mixed well
for an additional 5–20min incubation. The TransIT-
TKO transfection reagent–siRNA complex mixture was
subsequently added to the 6-well plate containing 1ml of
complete growth medium. After 72h of transfection, cell
lysates were prepared and subjected to western blot using
anti-TREX2 antibodies.
Cell cultureand immunostaining
All cell lines used in this study were from the American
Type Culture Collection (ATCC, Camden, NJ). HCT116
(human colon cancer epithelial cells); LoVo (human
colonrectal adenocarcinoma epithelial cells); Caco-2
(human colon cancer epithelial cells); CV-1/EBNA1
(human kidney normal ﬁbroblast transformed with
Epstein–Barr nuclear antigen 1); PC-3 (human prostate
epithelial cells); LNCap (human prostate epithelial cell);
HepG2 (human hepatocellular carcinoma cells); BG1
(ovarian cancer). The HeLa cells were derived from a
human cervical epitheloid carcinoma; HEK293 cells were
derived from an E1A-transformed human embryonic
kidney cell line. All the cell lines were cultured according
to ATCC instructions. For immunostaining, cells were
seeded at  20–30% conﬂuence on the chamber slides
Table 1. Oligonucleotides used in this study
Name Sequence Purpose
hTX25 50-AAAAAAGAATTCTCCGAGGCACCCCGGGCCGAGACCTTT-30 TREX2 subcloning
hTX23 50-AAAAAAAACTCGAGTCAGGCCTCCAGGCTGGGGTCATCA-30 TREX2 subcloning
hTX2-Kozak 50-CCGGAATTCGCCACCATGTCCGAGGCACCCCGGGCCGAG-30 TREX2 subcloning
hTX2L5 50-TGGCCTACGCCAAAGCACAGGATGG-30 TREX2 splicing form cloning
hTX2L3 50-TCAGGCCTCCAGGCTGGGGTCATC- 30 TREX2 splicing form cloning
hTX2-MIV5 50-CCGGAATTCATGATTGTGGCAGCAGAAGCCGTTGC-30 TREX2
L1 cloning
hTX2L2-5 50-CGCGGATCCATGATTGTGGCAGCAGAAGCCGTTGC-30 TREX2
L2 cloning
hTX2-945 50-ATGCCGGAAGGTGGCTTTGCTGGCGCCGTGGTGCGGACGC-30 D94A mutalion
hTX2-1075 50-GCAGGCCTTCCTGAGCGCCCAGGCAGGGCCCATCTGCC-30 R107A mutation
hTX2-191 50-AAGCGCAGCCCACTCAGCCGCGGGCGACGTGCACACCCTGC-30 H191A mutation
hTX2-295 50-GTGTGGAGCCCGAGATTGCCGCGCTGTCCCTCTTTGCTGTCCACC-30 E29A mutation
hTX2-595 50-CCTAGTATTGCCCGCGGTCCTGGACGCGCTCACGCTGTGCATG-30 K59A mutation
hTX2-55595 50-GTATTGCCCCGGGTCCTGGACGCGCTCACGCTGTGCATGTGC-30 R55A mutation
hTX2-R163A 50-CCCACAGCCACGGCACCGCGGCCCGGGGCCGCCAGGGTTAC-30 R163A mutation
hTX2-R165A 50-CAGCCACGGCACCCGGGCCGCGGGCCGCCAGGGTTACAGC-30 R165A mutation
hTX2-R167A 50-CGGCACCCGGGCCCGGGGCGCCCAGGGTTACAGCCTCGGC-30 R167A mutation
hTX2-H188A 50-CAGAGCCAAGCGCAGCCGCCTCAGCCGAGGGCGAC-30 H188A mutation
hTX2-D193A 50-CAGCCCACTCAGCCGAGGGCGCCGTGCACACCCTGCTCC-30 D193A mutation
hTX1-322 50-GTATGAGCTGCAGTTCCTCAGCAT-30 Substrate for exonuclease assay
Biotin-mTXl-322 Biotin-50-GTATGAGCTGCAGTTCCTCAGCAT-30 Substrate for SPR analysis
TX2siRNAlF 50-CGACGAGUCUGGUGCCCUAUU-30 TREX2 knockdown
TX2siRNAlR 50-UAGGGCACCAGACUCGUCGUU-30 TREX2 knockdown
TX2siRNA2F 5r-CCGGAAGGCUGGCUUUGAUUU-30 TRHX2 knockdown
TX2siRNA2R 50-AUCAAAGCCAGCCUUCCGGUU-30 TR1-X2 knockdown
TX2siRNA3F 50-ACAAUGGCUUUGAUUAUGAUU-30 TREX2 knockdown
TX2siRNA3R 50-UCAUAAUCAAAGCCAUUGUUU-30 TREX2 knockdown
hTX2LlF 50-AAGATCGAGTTGGCCGAGGATGG-30 RT-PCR
hTXL2F 50-GCTCCCAGAGCCAAAGGTCAC-30 RT-PCR
hTX2shortF 50-TTTGTCTTCCTGGACCTGGAA-30 RT-PCR
hTX2R 50-CCTGCAGCGTCCGCACCACG-30 RT-PCR
hTX2Ri 50-AGCGTGAGCTTGTCCAGGACC-30 RT-PCR
2684 Nucleic Acids Research, 2007, Vol. 35, No. 8(Nalge Nuc International Corp. Nalerville, IL). After 48h,
cells were rinsed with PBS once and then ﬁxed with 4% of
paraformaldehyde (dissolved in PBS) by incubating at
room temperature for 10min. After three washes with
PBS, cells were permeabilized with 0.3% Triton in TBST
for 10min at room temperature. Following permeabiliza-
tion, the cells were blocked with the blocking buﬀer (5%
non-fat milk in TBST) for 1–2h at room temperature, and
primary antibody (mouse anti-serum, 1:1000 dilution) was
subsequently incorporated to continue incubation for 1h
at room temperature. Upon the completion of primary
antibody incubation, the cells were washed three times
with TBST and were then incubated with blocking buﬀer
containing a ﬂuorescent-labeled secondary antibody
(Alexa Fluor488F(AB0)2 fragment of goat anti-mouse
IgG (HþL), Molecular Probe, OR, working dilution—
1:5000) for 1h at room temperature. After rinsing with
TBST for three to four times, one drop of DAPI-
containing mounting medium (VectorShield mounting
medium, Vector Laboratory, Inc.) was added to the
culture slide, and a coverslip was placed on top of the
mounting medium. Cells were immediately observed
under a Zeiss ﬂuorescent microscope.
Semi-quantitative RT-PCR
Total RNA was prepared from human cells with Trizol
Reagent (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s instructions and reverse transcribed
using oligo dT (SuperscriptII, Invitrogen, Carlsbad, CA,
USA). Human kidney mRNA was obtained from
Ambion. The conditions for all reactions are the same:
1 cycle of 988C for 5min followed by 35 cycles of 988C for
1min, 658C for 1min, 728C for 10s followed by 1 cycle of
728C for 10min.
To amplify a 410-bp mRNA fragment speciﬁc to
TREX2
L1, we used hTX2L1F (50-AAGATCGAGTTGG
CCGAGGATGG-30) and hTX2R (50-CTGCAGCGTCC
GCACCACG-30). The TREX2
L1 mRNA product was
re-ampliﬁed using hTX2L1F with an internal reverse
primer, hTX2Ri (50-AGCGTGAGCTTGTCCAGG
ACC-30) to amplify a 288-bp fragment.
To amplify a 364-bp mRNA fragment speciﬁc to
TREX2
L2, we used hTX2L2F (50-GCTCCCAGAGCC
AAAGGTCAC-30) and hTX2R (50-CCTGCAGCGTCC
GCACCACG-30). Since these primers failed to amplify a
spliced sequence from mRNA, genomic DNA was
successfully ampliﬁed to verify the quality of these primers
and conditions (not shown).
To amplify a 280-bp non-speciﬁc mRNA fragment
common to all isoforms, we used hTX2shortF
(50-TTTGTCTTCCTGGACCTGGAA-30) and hTX2R
(50-CTGCAGCGTCCGCACCACG-30). The TREX2
mRNA product was re-ampliﬁed using hTX2shortF with
an internal reverse primer, hTX2Ri (50-AGCGTGAGC
TTGTCCAGGACC-30) to amplify a 158-bp fragment.
GST pull-down assay
The cell lysate ( 500mg of total protein) extracted from
HEK293 cells 48h post-transfection with Flag-tagged
TREX2 was incubated with puriﬁed beads-bound GST-
fusion proteins ( 10mg) at 48C for 2h. Pull-down
products were washed three times by lysis buﬀer contain-
ing protease inhibitors. Bound proteins were separated by
SDS-PAGE, GST- and Flag-tagged protein, interaction
was detected by Coomassie staining and western blotting
with anti-Flag antibody.
Invitro exonuclease assay
A synthetic 24-mer oligonucleotide substrate (mTX1-322,
Table 1) was synthesized and subsequently radiolabeled by
g-
32P-ATP (PerkinElmer, Boston, MA, 250mCi, 5.0mCi/
ml) by the 50-end labeling protocol; ﬁrst, 50ml of labeling
reaction mixture containing 5mlo f1 0   T4 kinase buﬀer,
2ml (10units/ml) of T4 kinase, 3mlo fg-
32P-ATP, 1mlo f
5mM oligo and 29ml of distilled water was incubated at
378C for 30min. The labeling reaction was stopped by the
addition of stop buﬀer (a mixture of 400ml of 100%
ethanol alcohol, 150ml of ddH2O, 40ml of 3M NaAcetate
and 2mlo f1 0mg/ml yeast-tRNA), and incubated at  808C
for 30min. After centrifugation at 14000r.p.m. for
10min, the supernatant was removed and the pellet was
further washed by 100% ethanol alcohol once to remove
any free g-
32P-ATP. After air drying for a brief period, the
oligo was dissolved in 200ml of distilled water. The relative
radiation activity ( 2500c.p.m./pmol) of the probe was
determined by using liquid scintillation counter
(LS6000IS, Beckman). For a ‘standard’ in vitro exonu-
clease assay using puriﬁed TREX2 from E. coli, a reaction
mixture (20ml) consisting of 1ml (2.5pmol) of g-
32P-ATP-
labeled probe, and 4mlo f5   exonuclease buﬀer (100mM
Tris-HCl, pH 7.5, 10mM dithiothreitol, 25mM MgCl2,
and 500mg/ml bovine serum albumin) and 1ml of the
appropriate TREX2 dilution was used. TREX2 dilutions
were prepared in 1mg/ml bovine serum albumin at 48C.
Reactions were performed at 378C for 15min and were
subsequently quenched by the addition of 200mlo f
cold 95% ethanol. Samples were dried in vacuo and
re-suspended in 10ml of DNA sequencing loading dye.
Samples were heated at 728C for 5min, and 3ml of the
sample was subjected to electrophoresis on a 23%
polyacrylamide denaturing gel. After ﬁxing and drying,
the radiolabeled bands within the gel were visualized and
quantiﬁed by phosphorimager (Molecular Dynamics).
Measurementof TREX2–ssDNA interaction by surface
plasmonresonance
TREX2–ssDNA-binding analyses were performed using
Biacore2000 instrument (Biacore International AB,
Sweden). The biotinylated oligo (Biotin-50-GTA-TGA-
GCT-GCA-GTT-CCT-CAG-CAT-30) was synthesized
and diluted to a ﬁnal concentration of 10nM by the
running buﬀer (10mM Tris-HCl, pH 7.5, 2.5mM EDTA,
2.5mM DTT, 250mM NaCl, 10% glycerol and 0.02%
Triton X-100). The biotinylated ssDNA was immobilized
onto the sensor chip SA (streptavidin chip, Biacore
International AB, Sweden) to a ﬁnal density of 100–120
response units (RUs). One response unit corresponds to a
surface density of 0.73pg/mm
2 DNA (34). The chip
surface was regenerated with an injection of 20mlo f2M
NaCl. Puriﬁed wild-type or mutant TREX2 proteins were
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buﬀer and injected over ssDNA-immobilized and control
ﬂow-cells for 360s at a ﬂow rate of 30ml/min. TREX2–
ssDNA-binding ability and binding kinetic analysis
were performed using BIAevaluation4.1 global analysis
software. To estimate the relative DNA-binding capacity
of each mutant TREX2 compared to wild-type TREX2,
the maximum DNA-binding value (at 60 second after
injection) of each mutant protein is divided by the value of
wild-type TREX2 and then multiplied by 100%.
Cellsynchronization and cell cycle analysis byFACS
HeLa cells were grown to 60% conﬂuency in a DMEM
medium containing 10% calf serum and 1% GPS (2mM
glutamine, 30mg penicillin/ml and 50mg streptomycin/ml).
For double thymidine block (35), cells were blocked for
18h with 2mM thymidine and released for 9h by washing
out the thymidine. Cells were blocked again with 2mM
thymidine for 17h to arrest all the cells at the beginning of
S phase. The cells were released by washing out the
thymidine. Upon release from the thymidine block,495%
of the cells progress into S phase (0–4h), entered G2
(5–6h) and underwent a synchronous mitosis (M phase)
for 7–8h. Cells were collected at the following time
point: G1/S cells—0h; S-phase cells—2h and late S/G2
cells—5.5h. Mitotic cells were collected every 10min with
mild shaking and ﬂushing with PBS. The cells enriched
from each cell cycle phase were conﬁrmed by ﬂow
cytometry and the corresponding lysates were prepared
for western blot analysis.
Cellproliferation assayby TREX2–siRNA knockdown
Twenty-four hours before siRNA, HeLa cells (1 10
5
cells/well, 6-well plate) were seeded in a DMEM medium
containing 10% calf serum and 1% GPS. By the next day,
cells are at  60% conﬂuency, and the siRNA mix
(including three siRNA duplexes, Table 1) was transfected
by the same protocol as described in the previous sections.
Forty-eight hours post-transfection, complete DMEM
medium and 10% fetal bovine serum was replaced, and
cells were counted at 96hours post-transfection.
RESULTS
Expression of endogenousTREX2 and identification of two
alternatively splicedisoforms
Mouse anti-TREX2 antibodies were generated to better
understand the cellular characteristics of TREX2. Prior to
the examination of endogenous TREX2, the speciﬁcity of
these polyclonal antibodies was evaluated. Using direct-
and anti-Flag immunoprecipitation-western blot analysis
with mouse anti-TREX2 antibodies, a single protein band
with a molecular mass of  28kDa was clearly detected in
extracts prepared from HEK293 cells transiently trans-
fected with the pCMV-Flag-TREX2 expression vector
(Figure 1A, lane 6, 8 and 10). The same band was absent
in either extracts prepared from empty vector-transfected
HEK293 cells or the immunoprecipitation complex by
pre-immune serum (Figure 1A, lines 5, 7, and 9),
indicating that anti-TREX2 antibodies speciﬁcally recog-
nize recombinant Flag-TREX2 with nearly no back-
ground (Figure 1A-c). We observed that the level of
endogenous TREX2 in HEK293 cells, but not in other
human cell lines (see below), is too low to be detected
(Figure 1A, lanes 5 and 7). To verify the potential cross-
reactivity of anti-TREX2 antibodies to TREX1 because of
their peptide sequence homology, the HEK293-expressed
Flag-TREX1 or Flag-TREX2 was subjected to western
blot with anti-Flag, anti-TREX1 or anti-TREX2 anti-
bodies. Anti-TREX2 antibodies speciﬁcally detect recom-
binant Flag-TREX2 (Figure 1B), but not Flag-TREX1 or
other cellular proteins, showing that anti-TREX2 anti-
bodies are highly speciﬁc to TREX2.
To detect endogenous TREX2, lysates prepared from
mouse lung, liver, kidney, spleen, brain, testis and heart
were separated by SDS-PAGE gel followed by western
blot with anti-TREX2 antibodies. A protein band with the
predicted molecular weight ( 26kDa) was detected in all
tissues (Figure 2A), displaying an expression pattern
similar to the transcription pattern using human tissues
(26). To extend this ﬁnding, extracts from human cell lines
were examined by the same approach. To our surprise, a
single major protein band with a molecular mass of
30kDa, rather than 26kDa, was detected in all human cell
lines (Figure 2B) except HEK293 cells, in which no signal,
Figure 1. Anti-TREX2 polyclonal antibody development. (A)
Detection of Flag-TREX2 expression in HEK293 cells by anti-
TREX2 polyclonal anti-serum. E: pCMV-Flag; T: pCMV-Flag-
TREX2. (a) Coommassie stain for total loading of cell lysates;
(b) immunoblot by pre-immune serum; (c) immunoblot by anti-
TREX2 anti-serum; (d) immunoblot by anti-Flag; (e) anti-Flag
immunoprecipitation followed by immunoblot with anti-TREX2 anti-
body. (B) Test cross-reactivity of anti-TREX2 antibody to TREX1.
Empty vector: EV; TREX1: TX1; TREX2: TX2. b-Actin serves as an
internal loading control.
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lanes 1 and 2). To further verify this result, we did
immunoprecipitation (IP)-western blot using mouse anti-
TREX2 antibodies or pre-immune serum. Our results
show that the 30-kDa protein band is immunoprecipitated
speciﬁcally by anti-TREX2 antibodies, but not by pre-
immune serum, indicating that the 30-kDa protein band is
likely the endogenous human TREX2 (Figure 2C).
Nevertheless, we observed a weak protein band corre-
sponding to 26kDa in an anti-TREX2 immunoprecipita-
tion-western blot while it is under detectable limits in a
direct western blot (Figure 2C, lane 2 and Figure 2B),
suggesting that it is likely 26-kDa TREX2. To conﬁrm the
identity of the 30-kDa protein band, we introduced
human TREX2 small interference RNA (siRNA) into
HeLa cells. All three independent TREX2–siRNA
duplexes (Table 1), but not the control siRNA, signiﬁ-
cantly reduced the 30-kDa protein band but not endo-
genous b-actin (Figure 2D), thus providing strong
evidence that the 30-kDa protein band is endogenous
human TREX2.
There are two possibilities to account for endogenous
human TREX2 migrating at 30kDa rather than 26kDa:
(1) post-translational modiﬁcation or (2) expression of
bigger isoforms. To determine the nature of this 30-kDa
protein, Flag-tagged and non-tagged TREX2 expressed in
either HEK293 or HeLa cells were compared to endogen-
ous human TREX2 by SDS-PAGE gel electrophoresis
followed by western blot using mouse anti-TREX2
antibodies (Figure 2E). Non-tagged and Flag-tagged
recombinant TREX2 migrate at their predicted molecular
weights, 26 and 28kDa, respectively (Figure 2E, lanes 1, 2
and lane 3 lower band), smaller than endogenous human
TREX2 (30-kDa, Figure 2E, lanes 3 and 4); thus, the slow
migration of endogenous human TREX2 is not due to
post-translational modiﬁcation of the previously reported
26-kDa protein. To test whether the 30-kDa human
TREX2 is a bigger isoform, we isolated longer TREX2
mRNA from a pool of 33 human tissues using primers
corresponding to exons 15 and 16 of the reported TREX2
gene, AF319571 (26). As a result, two longer spliced
isoforms were identiﬁed, called TREX2
L1 and TREX2
L2.
TREX2
L1 is spliced by two exons, encoding a 279-amino-
acid peptide identical to NP_542431 (Figure 3A),
while TREX2
L2 is novel and results from three spliced
exons encoding a 278-amino-acid peptide, ABG43103
(Figure 3A). Both of these alternatively spliced isoforms
contain an extra peptide sequence (either 43 or 42 amino
acids) fused to the N-terminus of the previously reported
26-kDa sequence (Figure 3B). The predicted molecular
weight of these two long isoforms is 30kDa, consistent
with the molecular weight of endogenous human TREX2.
Collectively, these long isoforms are predominantly
expressed in human cells compared to the 26-kDa isoform
(Figure 2B) while the short isoform is predominantly
expressed in mouse tissues (Figure 2A).
To further evaluate these long isoforms, we performed a
semi-quantitative RT-PCR on mRNA isolated from ﬁve
human cell lines (HeLa, LoVo, HCT116, PC3 and BG1)
and one tissue (kidney) using primers speciﬁc to TREX2
L1
and TREX2
L2. We also used primers located to the short
Figure 2. Expression of endogenous TREX2 in mouse tissues and
human cell lines. (A) Mouse tissues. Lanes 1 and 2: lysates from human
HEK293 cells transiently transfected with TX2 (pCMV-Flag-TREX2)
or EV (pCMV empty vector). Flag-TREX2 is the fusion product of
19 amino acids (including Flag-peptide) fused with the 26-kDa human
TREX2 ORF. The predicated molecular weight is 28kDa. (B) Human
cell lines. Flag-TREX2: lysate from pCMV-Flag-TREX2-transfected
HEK293 cells. (C) Immunoprecipitation-western blot using HeLa cells.
Immunoprecipitation complex by either pre-immune serum (lane 1) or
anti-TREX2 antibodies (lane 2) was resolved by SDS-PAGE,
followed by anti-TREX2 western blot. (D) Endogenous
TREX2–siRNA knockdown. HeLa cells transfected with each of
TREX2–siRNA duplexes (lanes 1, 2 and 3, Table 1) or control
siRNA (lane C) were collected 72h post-transfection. Cell lysates were
prepared and subjected to western blot with anti-TREX2 antibody.
b-Actin serves as a loading control. (E) Examination for post-
translational modiﬁcation of TREX2. Lane 1: 26-kDa TREX2
open-reading frame (ORF) (25) expressed in HEK293 cells. Lane 2:
Flag-tagged 26-kDa TREX2 expressed in HEK293 cells. Lane 3: Flag-
tagged 26kDa TREX2 expressed in HeLa cells. Lane 4: empty vector-
transfected HeLa cells.
Nucleic Acids Research, 2007, Vol. 35, No. 8 2687Figure 3. Human TREX2 isoforms. (A) Genomic structure of the human TREX2 gene. Human TREX2, located on chromosome X, contains
16 exons (26), of which only exons 15 and 16 are shown. TREX2
L1 (NP_542431) is a spliced product of exons 15 and 16. TREX2
L2 is a novel spliced
product of exons 15, 15b and 16. The nucleotide sequence for TREX2
L2 has been deposited in the GenBank database under accession number
DQ650792. The amino acid sequence of TREX2
L2 can be accessed through NCBI Protein Database under NCBI access number ABG43103. Oval
indicates the predicated promoter region. (B) Protein sequence alignment of three TREX2 isoforms. TREX2
L1 encodes a 279-amino-acid peptide and
TREX2
L2 is a 278-amino-acid peptide. Both TREX2
L1 and TREX2
L2 have a predicated molecular weight of  30kDa. Red depicts identical
homology among the three TREX2 isoforms; blue depicts identical homology between the two longer isoforms; black dots show the diﬀerence
between the two longer isoforms. (C) Semi-quantitative RT-PCR to detect the TREX2 isoforms in cancer-derived human cells (HeLa, HCT116,
LoVo, PC3 and BG1) and human kidney. The TREX2
L1 isoform (upper panel) is ampliﬁed with primers hTX2L1F (half arrow in the yellow exon)
and hTX2R (white half arrow in the red exon). As a control, hTX2short (black half arrow in the red exon) and hTX2R were used to amplify the
product common to all isoforms (lower panel). These products were re-ampliﬁed with the same forward primer and a new internal primer, hTX2Ri
(green half arrow in the red exon). This TREX2
L1 product was sequenced to verify the results. We used hTX2L2F (half arrow in the orange exon)
and hTX2R in our attempt to amplify the TREX2
L2 isoform; however, no product was seen. PCR was performed with diﬀerent concentrations of
cDNA (mg).
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contain this region). We ﬁnd that TREX2
L1 is the
predominant and possibly only transcript for all samples
since TREX2
L1 levels are equal to that of the short
isoform (Figure 3C). These transcripts were veriﬁed as
being TREX2
L1 by re-ampliﬁcation using an internal
reverse primer along with the original forward primer and
then by sequencing this re-ampliﬁcation product. Since
TREX2
L2 was not detected in these samples but present in
a mixture of 33 human tissues, we anticipate that
expression of TREX2
L2 is likely restricted to a subset of
speciﬁc tissues or cell types.
Structure–function analysis ofTREX2 functional domains
Based on the peptide sequence alignment and the X-ray
structural similarity between TREX2 and bacterial DNA
polymerase III e subunit, TREX2 is proposed to possess
three functional domains important for three distinct
activities: homodimerization, DNA binding and exonu-
clease activity (29). In the same study, the amino acids
critical for each functional activity have been proposed:
arginine 163, 165 and 167 for DNA-binding ability;
histidine 188 and aspartic acid 193 for exonuclease
activity; and glutamic acid 29, arginine 55, lysine 59,
aspartic acid 94, arginine 107 and glutamic acid 191 for
dimerization (29). To further map the functional con-
tribution and the coordination of these three functional
domains, we ﬁrst investigate TREX2 (the 26-kDa isoform)
with multiple mutations in each domain: homo-
dimerization defective (TREX2
DD, E29A/K59A/D94A/
R107A/E191A), DNA-binding defective (TREX2
BD:
R163A/R165A/R167A) and exonuclease catalytic
defective (TREX2
CD: H188A/D193A). We then investi-
gate TREX2 with single amino acid changes for each
domain using highly puriﬁed proteins (Figure 4A and B).
In addition, we investigate the three in vitro activities of
the long TREX2 isoforms, TREX2
L1 and TREX2
L2.
Homodimerization is measured by a GST pull-down
assay (Figure 4C, D). We ﬁnd TREX2, TREX2
L1 and
TREX2
L2 are able to self-associate. In fact, self-associa-
tion is not measurably diminished for any of the altered
TREX2 proteins with the exception of TREX2
DD
(Figure 4C and D). These results indicate that the
combination of amino acids in the homodimerization
domain (E29, K59, D94A, R107A and E191) is essential
for TREX2 dimerization.
DNA binding is evaluated by a real-time DNA-binding
assay based on surface plasmon resonance (SPR) that
shows TREX2 directly binds to a single-strand DNA
(ssDNA) substrate (Table 1) with a moderate binding
aﬃnity (Figure 5A; KD¼7.51 10
 7, 
2¼2.72).
TREX2
L1 and TREX2
L2 bind to this ssDNA substrate
with  80 and  120% aﬃnity relative to TREX2,
respectively. In contrast, TREX2
BD (R163A, R165A and
R167A) is completely unable to bind to the ssDNA
substrate (Figure 5B and C) and diﬀers from the
previously published result, which showed that the same
mutations reduced TREX2–DNA-binding activity by
 90-fold (29). This discrepancy likely reﬂects the diﬀerent
methodologies used in these studies, the former study
is based on the steady-kinetic analysis by calculating
the kcat/Km while our study evaluates the real-time
TREX2–DNA-binding kinetics by SPR technology.
Using an electrophoretic mobility shift assay (EMSA),
we ﬁnd that TREX2
BD, like TREX2, binds DNA
substrate (data not shown), indicating that EMSA
or kcat/Km calculation is less stringent than SPR analysis.
To extend this ﬁnding, we further ﬁnd single amino
acid changes for two of these amino acids (R165A
and R167A) impair DNA binding by  80%; however,
changing the third amino acid (R163A) had only
a marginal impact ( 20%). Like TREX2
BD, TREX2
DD
is completely unable to bind to the ssDNA substrate,
and the single amino acid changes in this domain also
severely impair substrate binding (490% defective)
suggesting that homodimerization is essential for the
TREX2–DNA substrate interaction. Unexpectedly,
TREX2
CD is also severely impaired ( 90%) while single
amino acid changes are moderately impaired ( 60%) for
substrate binding indicating that H188 and D193 are not
only essential for catalytic activity, but also important for
DNA binding.
Figure 4. TREX2 self-association using puriﬁed proteins.
(A) Puriﬁcation of TREX2 (TX2), TREX2
BD (BD), TREX2
DD (DD)
or TREX2
CD (CD). Here, 1mg of bovine serum albumin (BSA) is
loaded to estimate the concentration of puriﬁed TREX2 proteins.
(B) Puriﬁcation of TREX2, TREX2
L1 (L1), TREX2
L2 (L2) and TREX2
with single amino acid changes. (C and D) GST pull-down assay. The
same amount ( 10mg) of GST-TREX2 fusion protein is incubated with
an equal amount ( 5mg) of cell lysates prepared from HEK293 cells
transiently transfected with Flag-tagged TREX2. The GST pull-down
complexes were separated by SDS-PAGE followed by either Coomassie
stain or anti-Flag western blot.
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exonuclease assay as previously described (25). TREX2,
TREX2
L1 and TREX2
L2 exhibit the same level of catalytic
activity while TREX2
CD and TREX2 with single amino
acid changes in this domain (H188A or D193A) are
completely defective for exonuclease catalytic activity even
at high protein concentrations (Figure 6A, B), consistent
with previous results (29). Like TREX2
CD, TREX2
DD
possesses no catalytic activity even at high protein
concentrations and changing most of the amino acids in
this domain greatly reduces catalytic activity (R55A, K59A
and D94A—completely ablate activity; E29A and
R107A—severely diminish activity; and E191A—moder-
ately diminishes activity) (Figure 6C, D). Interestingly,
TREX2
BD displays moderately reduced catalytic activity
compared to TREX2, but the single amino acid changes do
not diminish activity.
Cellular characteristics of endogenous TREX2
Endogenous TREX2 was investigated for subcellular
localization, cell cycle distribution and RNAi knockdown.
To determine TREX2 subcellular localization, HeLa cells
were immunostained using mouse anti-TREX2 anti-
bodies. We ﬁnd endogenous human TREX2 is localized
in both the nucleus and cytoplasm. Interestingly, nuclear
TREX2 displays a punctuate staining pattern with  3–5
foci/cell (Figure 7A), a common characteristic shared by
proteins participating in DNA damage checkpoints, DNA
repair and replication. To investigate whether endogenous
TREX2 expression is regulated during the cell cycle, HeLa
cells were synchronized at G1/S by double-thymidine
block (35), as conﬁrmed by ﬂow cytometry (Figure 7B).
Cells form each phase of the cell cycle were collected and
cell lysates were analyzed by western blot using mouse
anti-hTREX2 antibodies. Our results show that endogen-
ous TREX2 levels are regulated through the cell cycle with
the lowest expression level in G2/M (Figure 7C), indicat-
ing that TREX2 plays a unique function in speciﬁc cell
phases such as G1/S and S. RNAi knockdown was used to
determine the impact loss-of-TREX2 function has on cell
proliferation. The depletion of endogenous TREX2 in
HeLa cells signiﬁcantly reduces cell proliferation
(P50.012) (Figure 7D). Taken together, these results
suggest that TREX2 plays an important role in regulating
cell proliferation.
DISCUSSION
Here, we investigate the cellular and biochemical proper-
ties of the 30 !50 exonuclease, TREX2. We ﬁnd that
TREX2 is commonly expressed in a wide range of mouse
tissues and human cell lines and have identiﬁed at least
three TREX2 isoforms generated by alternative splicing
that include a 26-kDa isoform and two 30-kDa isoforms.
These isoforms function equally well for homodimeriza-
tion, DNA binding and exonuclease activity. For the
26-kDa isoform, we ﬁnd that both DNA binding and
catalytic activity depend on eﬃcient self-association while
DNA binding and exonuclease activities may be partly
separated from each other. These activities are likely
important for genome metabolism as supported by our
observations that TREX2 forms nuclear foci, is cell cycle
regulated and important for cellular proliferation.
We did not expect to ﬁnd TREX2 to be predom-
inately expressed as a 30-kDa protein rather than
the 26-kDa protein in human cells. We provide ﬁve
lines of evidence that support this 30-kDa protein
is TREX2. First, the 30-kDa protein band is
not endogenous TREX1 ( 33kDa) non-speciﬁcally
recognized by anti-TREX2 antibodies because no
Figure 5. TREX2–ssDNA real-time binding kinetics by surface
plasmon resonance. (A) Binding kinetics. A series of diluted 26-kDa
TREX2 were injected into the streptavidin-coated sensor chip
immobilized with 100 RU of ssDNA. Kinetic analyses of sensorgrams
were performed using BIAeval 4.1 global analysis software, and
manually using spreadsheet and graphing software. (B) Real-time
ssDNA-binding capacity of 26-kDa TREX2 and mutant TREX2at
480nM. Calculation of the relative binding is described in Methods and
Materials. (C) Graph demonstrating the average of three experiments.
Maximum ssDNA-binding eﬃciency shown relative to TREX2 (TX2).
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is detected (Figure 1B). Second, the 30-kDa protein band
is clearly detected as a single major band in both direct-
and immunoprecipitation-western blot by using anti-
TREX2 antibodies, but not pre-immune serum (Figure
2B and C). Third, the 30-kDa protein band is speciﬁcally
knocked down by three independent human TREX2–
siRNA duplexes, but not by a control siRNA duplex
(Figure 2D). Fourth, 26-kDa TREX2 is not modiﬁed to
result in a 30-kDa protein band since neither Flag-tagged
nor non-tagged 26-kDa TREX2 migrates at 30-kDa when
transfected into human cells (Figure 2E). Fifth, two
alternatively spliced isoforms, TREX2
L1 and TREX2
L2,
were isolated, and these isoforms code for proteins
predicted to be  30 kDa (Figure 3). In addition, these
long isoforms are completely functional for self-associa-
tion, DNA binding and exonuclease activity (Figure 4–6).
Taken together, our results support that the predomi-
nantly expressed endogenous 30-kDa protein is endogen-
ous human TREX2. Because TREX2
L1 and TREX2
L2
were isolated based on an mRNA pool of 33 human
tissues, we cannot conclude whether these isoforms
display diﬀerent tissue expression patterns at this time
since this will require further investigation by using
antibodies that speciﬁcally recognizing the 30-amino-acid
peptide at the N-terminus. Unlike human TREX2,
endogenous mouse TREX2 is predominantly detected as
the 26-kDa isoform. Interestingly, a  30-kDa protein
band was also observed in mouse kidney and testis, but
not in other tissues, co-existing with 26-kDa TREX2
(Figure 2A), suggesting multiple TREX2 isoforms exist in
mouse tissues as well.
The X-ray structure and amino acid conservation
predict three domains for TREX2 that are important for
homodimerization, DNA binding and exonuclease activ-
ity. We have developed three assays to evaluate each
activity for a variety of mutants designed to disrupt only
one domain. For the homodimerization domain, we ﬁnd
that the self-association is defective only when TREX2
contains ﬁve mutations. This highly altered protein is also
Figure 6. In vitro exonuclease assay. No TREX2 was used to serve as negative control ( ). (A) Picograms (500, 250, 125, 62.5, 31, 16 and 8) and
(B) nanograms (50, 25 and 12.5) of protein are shown for TREX2 (TX2), TREX2
BD (BD), TREX2
DD (DD) or TREX2
CD (CD). (C) Picograms
(100, 50 and 25) and (D) nanograms (50, 25 and 12.5) of protein are shown for TREX2, TREX2
L1 (L1), TREX2
L2 (L2) and TREX2 with single
amino acid changes.
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ities. Therefore, TREX2 was altered for only single amino
acids within this domain and these TREX2 mutants are
not obviously defective for self-association, but are
severely defective for both DNA binding and catalytic
activities demonstrating the importance for optimal self-
association. Consistent with this ﬁnding, mutation of
TREX1 R114 (equivalent to TREX2 R107) identiﬁed
from Aicardi-Goutieres syndrome patients impairs cata-
lytic activity (31). For the DNA-binding domain, TREX2
with three mutations has no observable impact on self-
association but severely disrupts both DNA binding and
catalytic activity. TREX2 with single amino acid muta-
tions in this domain shows that two of these amino acids
(R165 and R167) are critical for fully eﬃcient DNA
binding each displaying an  80% decline; however, both
mutants exhibit strong exonuclease activity. Thus, eﬃcient
exonuclease activity does not require eﬃcient DNA
binding, at least in vitro. Contrary to the X-ray structural
prediction, mutation of R163 barely aﬀects DNA binding
even though this amino acid may be required for fully
optimal binding. For the exonuclease domain, TREX2
with two mutations has no impact on self-association but
severely disrupts its predicted activity as shown previously
(29) and also impairs DNA binding by  90%. TREX2
with single amino acid mutations in this domain show that
each amino acid is critical for catalytic activity and
important for fully eﬃcient DNA binding since each
mutant exhibits no catalytic activity and  60% reduction
in DNA binding. Thus, amino acids essential for catalytic
function are also important for eﬃcient DNA binding.
The genetic screen for TREX2 SNPs has led to the
identiﬁcation of S39F, R137 and R156L in prostate cancer
clinical samples, but these mutations do not alter TREX2
in vitro exonuclease activity (36). It would be interesting to
know whether DNA-binding activity or homodimer
formation was aﬀected by the mutation of S39F, R137
and R156L, thus altering the cellular function of TREX2.
TREX2 exhibits cellular characteristics that suggest its
function supports genome integrity and cellular prolifera-
tion. We ﬁnd that TREX2 forms nuclear foci and TREX2
levels are regulated during the cell cycle with the lowest
expression during G2/M phase. Similarly, the other
closely related 30!50 exonuclease, TREX1, is also cell
cycle regulated, with the highest expression level in S-
phase and the lowest in M phase (35). In accordance with
this observation, TREX2 has been reported to associate
with replication proteins that include pold (28) and the
virus replication machinery (37) suggesting a role during
DNA replication. However, the exact role of TREX2 in
DNA replication remains to be investigated.
In summary, we have characterized the biochemical and
cellular characteristics of TREX2. We ﬁnd that TREX2 is
expressed in most tissues and cells, and endogenous
human TREX2 is dominantly expressed as a 30-kDa
protein, likely encoded by either TREX2
L1 and/or
TREX2
L2. TREX2 forms nuclear foci and its levels are
cell cycle regulated. TREX2 possesses at least three
basic biochemical functions: homodimerization, DNA
binding and enzymatic activity, and these functions
are co-dependent, in particular, fully eﬃcient
Figure 7. Cellular characteristics for TREX2. (A) Subcellular localiza-
tion of TREX2 in HeLa cells that were ﬁxed, permeablized
and incubated with either anti-TREX2 antibodies (upper panel) or
pre-immune serum (lower panel). (B) HeLa cells in diﬀerent cell
cycle phases (G1/S, S, late S/G2, G2/M) were collected and veriﬁed by
ﬂow cytometry analysis of propidium-iodide-stained cells. (C) Cell
lysates prepared from each cell phase were analyzed by SDS-PAGE
followed by anti-TREX2 western blot. AS: asynchronized cells; S/G2:
late S/G2. (D) HeLa cells (1 10
5) transfected with either TREX2–
siRNA or control siRNA; 96-h post-transfection, cells were counted.
Cell proliferation rate represents the ratio of the number of cells in
experimental group divided by the number of cells in control group.
This graph is calculated based on three independent transfected wells
for each treatment.
2692 Nucleic Acids Research, 2007, Vol. 35, No. 8homodimerization seems to be required for both DNA
binding and exonuclease activity, and the exonuclease
domain seems to be required for fully eﬃcient DNA
binding. Even though these domains are co-dependent, the
DNA catalytic activity does not require fully eﬃcient
DNA binding by our in vitro assays. Finally, cellular
studies show that TREX2 is important for cell prolifera-
tion. Collectively, our results suggest that TREX2 plays
an important role in DNA metabolism and cell
proliferation.
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